Results 81 to 90 of about 54,917 (299)

The journey from gene knockout to clinical medicine: telotristat and sotagliflozin

Drug Design, Development and Therapy, 2019
Marc S Rendell1,2 1Association of Diabetes Investigators, Omaha, NE 68131, USA; 2Rose Salter Medical Research Foundation, Newport Coast, CA 92657, USA Abstract: Gene knockout has been a powerful technique to evaluate the physiologic role of selected ...
Rendell MS
doaj  

SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis

Cardiovascular Diabetology, 2023
Background Sodium–glucose transporter 2 inhibitors (SGLT2-I) could modulate atherosclerotic plaque progression, via down-regulation of inflammatory burden, and lead to reduction of major adverse cardiovascular events (MACEs) in type 2 diabetes mellitus ...
Celestino Sardu, Maria Consiglia Trotta, Ferdinando Carlo Sasso, Cosimo Sacra, Gerardo Carpinella, Ciro Mauro, Fabio Minicucci, Paolo Calabrò, Michele D’ Amico, Fabrizio D’ Ascenzo, Ovidio De Filippo, Mario Iannaccone, Carmine Pizzi, Giuseppe Paolisso, Raffaele Marfella   +14 more
doaj   +1 more source

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source

Socio‐economic inequalities and heart failure morbidity and mortality: A systematic review and data synthesis

ESC Heart Failure, Volume 12, Issue 2, Page 927-941, April 2025.
Abstract Socio‐economic status (SES) has been associated with incident and prevalent heart failure (HF), as well as its morbidity and mortality. However, the precise nature of the relationship between SES and HF remains unclear due to inconsistent data. This study aims to provide a comprehensive assessment and data synthesis of the relationship between
Abdul Shakoor, Willemijn A. van Maarschalkerwaart, Jeroen Schaap, Rudolf A. de Boer, Nicolas M. van Mieghem, Eric H. Boersma, Loek van Heerebeek, Jasper J. Brugts, Robert M.A. van der Boon   +8 more
wiley   +1 more source

Chances and risks of SGLT2 inhibitors [PDF]

Naunyn-Schmiedeberg's Archives of Pharmacology, 2011
Type II diabetes mellitus (T2DM) is characterised by relative insulin deficiency caused by resistance of important target organs like liver and skeletal muscle towards insulin. During the course of the disease, pancreatic insulin production becomes decreased, and absolute insulin deficiency results (Kahn 2003).
openaire   +2 more sources

Incident heart failure: comparing management and outcome in primary and hospital settings in Western Sweden 2008–2017

ESC Heart Failure, Volume 12, Issue 2, Page 832-838, April 2025.
Abstract Aim Heart failure (HF) is a highly prevalent condition managed in both primary care (PC) and hospital care (HC)‐based settings. HF patients managed in these two settings may differ in their demography, comorbidities and outcomes, so we aimed to compare the patient management in PC and HC in the Västra Götaland Region (VGR) in Sweden.
Xiaojing Chen, Aldina Pivodic, Maria Schaufelberger, Annika Rosengren, Michael Fu   +4 more
wiley   +1 more source

The Impact of SGLT2 Inhibitors on Hemoglobin Levels in Type 2 Diabetes: Potential Benefits Beyond Glycemic and Renal Outcomes [PDF]

Aim: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are antidiabetic agents with proven cardiovascular and renal benefits. Recent evidence suggests they may also increase hemoglobin (Hb) levels through mechanisms beyond hemoconcentration.
Nilsu Kalayci, Emre Hoca
core   +1 more source

MELD score predicts outcomes in patients with advanced heart failure: A longitudinal evaluation

ESC Heart Failure, Volume 12, Issue 2, Page 839-847, April 2025.
Abstract Aims Advanced heart failure (AHF) is characterized by recurrent episodes of haemodynamic instability and frequent hospitalizations, leading to a progressive decline in quality of life and high mortality rates. The objectives of this study were to evaluate the effect of the model for end‐stage liver disease (MELD) score and its variations in ...
Francesco Curcio, Cristiano Amarelli, Rosaria Chiappetti, Irene Mattucci, Veronica Flocco, Mahmoud Issa Rammal, Ciro Abete, Francesca Mazzella, Ciro Maiello, Pasquale Abete, Francesco Cacciatore   +10 more
wiley   +1 more source

The regulation of SGLT2.

, 2013
SGLT2 expression is not regulated by high glucose (A) but is increased with TGFβ1(B) in HK2 cells after 48 hours (B). Chromatin immunoprecipitation assay showed significantly increased binding of phosphosmad3 to the relevant binding site in the promoter ...
Simon Gross (285318), Carol Pollock (279260), Kate Pegg (285316), Amanda Mather (285324), Harshini Mudaliar (285321), Usha Panchapakesan (285314), Josephine Forbes (285322), Muralikrishna Gangadharan Komala (285320)   +7 more
core   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source